| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.093 | 0.003 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.095 | 0.003 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |